CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 46 enrolled / 46 target
Drug / intervention
Cetaphildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06357221
NCT06357221Phase 4CompletedOn Track (1.7/mo)Completion was 23mo ago
CompareCT.gov

A Multi-center, Open-label, In-use Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients

Galderma R&D·interventional·Posted Apr 10, 2024·Updated Jun 9, 2026

In Brief

A Phase 4 clinical trial evaluating Cetaphil for Plaque Psoriasis and Psoriasis. Completed, enrolled 46 participants across 3 sites.

Detailed Summary

Subjects having mild-to-severe plaque psoriasis, with active target lesion plaques, and currently on or starting a prescription treatment for plaque psoriasis will apply a topical skincare regimen to one side of the body. Evaluations of the regimen's efficacy will be conducted at 2 weeks, 4 weeks, and 8 weeks post-baseline.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis, Psoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20252026
First PostedApr 10, 2024
Enrollment StartApr 8, 2024
Primary CompletionJul 18, 2024
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 2.2 years ago

Arms & Interventions

Skincare Product Treatmentexperimental

Subjects will use topical skincare products to assigned side of the body, per randomization.

Drug: Cetaphil

Interventions

Cetaphildrug

Subjects will clean the skin with Cetaphil Gentle Skin Cleanser, and apply Cetaphil Moisturizing Cream to the lesion areas at least twice daily. Subjects will use Cetaphil Daily Facial Moisturizer SPF 35 as needed.